Summit Therapeutics PLC (LON:SUMM) CEO Glyn Edwards sat down with Proactive at the 2019 BIO Investor Forum where is explained anti microbial resistance will be as big a problem as climate change.
Edwards says recently, Summit reported that Phase II trials showed that antibiotic Ridinilazole can kill C.difficile infections while preserving healthy microorganisms in the gastrointestinal tract. Summit remains on track to deliver Phase III data for its antibiotic Ridinilazole in the second half of 2021.